• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Arsenal Capital Partners acquires Certara

Arsenal Capital Partners acquires Certara

December 20, 2013
CenterWatch Staff

Arsenal Capital Partners, a New York-based private equity firm that invests in middle market healthcare and specialty industrial companies, has acquired Certara, a provider of model-based drug development and data analytics software and consulting services to the biopharmaceutical R&D market.

Certara provides highly specialized and integrated solutions that consist of computer-based models supported by scientific consulting services and span the discovery, preclinical and clinical stages of drug development. Certara's solutions provide clients with significant reductions in the time and expense of bringing new drugs to market by enabling data-driven decisions, which lead to more precisely designed studies with less risk of failure and improved subject safety.

Stephen McLean, a partner at Arsenal and co-head of the firm's healthcare group, said, "The average cost today of researching and developing a new drug is over $1.5 billion and takes 10 to 15 years. This is clearly inconsistent with the imperative of reducing the costs of global healthcare, and Certara will make a difference."

Dr. James Rothman, a recipient of the 2013 Nobel Prize in Physiology or Medicine, who evaluated the Certara acquisition in his role in Arsenal Capital Partners' healthcare group, said Arsenal was interested in the acquisition because of Certara's ability to increase both the effectiveness and efficiency of the drug development process. "Model-based drug development is allowing pharmaceutical and biotechnology companies to adopt a more rigorous, quantitative approach to drug development. This allows more informed decisions to be made about which drug candidates to move forward and how to optimize clinical trial designs, which is better for the industry and ultimately for patients," said Rothman, who will become a Certara board member.

Dr. Donald A. Deieso, operating partner and co-head of Arsenal's healthcare group, said, "Technology-driven informatics models will not only result in more cost-effective drug development, but also will be the foundation for delivering personalized medicine and clinical care. We plan to build upon Certara's existing drug development software and consulting services to make the company an even stronger, more versatile partner for its pharmaceutical and biotechnology customers and ultimately execute on Arsenal's vision of personalized medicine."

Arsenal's Certara acquisition follows its 2012 purchase and consolidation into the WIRB-Copernicus Group (WCG) of the Western Institutional Review Board (WIRB), the Copernicus Group IRB and IRBNet. The acquisition of Certara expands the range of services its portfolio companies can offer to pharmaceutical and biotechnology firms and CROs. WCG provides independent IRB services and operates federally-mandated IRB panels.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing